Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Orantinib
299
CHF
CHF 299.00
In stock
CDX-O0202-M02525 mgCHF 299.00
CDX-O0202-M100100 mgCHF 896.00
| Product Details | |
|---|---|
| Synonyms | TSU68; SU 6668; NSC 702827; 5-[1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid |
| Product Type | Chemical |
| Properties | |
| Formula | C18H18N2O3 |
| MW | 310.35 |
| CAS | 252916-29-3 |
| RTECS | UX9641810 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Orange to red solid. |
| Solubility | Soluble in DMSO (10mg/ml) or DMF (5mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | NHFDRBXTEDBWCZ-ZROIWOOFSA-N |
| Smiles | O=C1NC2=CC=CC=C2/C1=C/C3=C(C)C(CCC(O)=O)=C(C)N3 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Orantinib is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. It is a potent ATP-competitive inhibitor of PDGFRβ, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 μM, respectively) but not EGFR (IC50 >100 μM). Orantinib suppresses tumor growth, blocks angiogenesis in tumors and induces apoptosis of tumor vasculature and regression of established tumors. Orantinib inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells, inhibits Aurora kinases B and C (IC50=35 and 210nM, respectively), and inhibits Unc-51-like serine/threonine kinase Ulk3, involved in hedgehog signaling. All together ornatinib exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity.
Product References
(1) L. Sun, et al.; J. Med. Chem. 42, 5120 (1999) | (2) A.D. Laird, et al.; Cancer Res. 60, 4152 (2000) | (3) B.D. Smolich, et al.; Blood 97, 1413 (2001) | (4) A.D. Laird, et al.; FASEB J. 16, 681 (2002) | (5) K. Godl, et al.; Cancer Res. 65, 6919 (2005) | (6) D.W. Kim, et al.; J. Clin. Endocrinol. Metab. 91, 4070 (2006) | (7) J. Bain, et al.; Biochem. J. 408, 297 (2007) | (8) M. Yamamoto, et al.; Cancer Res. 68, 9754 (2008) | (9) N. Kammasud, et al.; Bioorg. Med. Chem. Lett. 19, 745 (2009) | (10) A. Piirsoo, et al.; Biochim. Biophys. Acta 1843, 703 (2014) | (11) L. Kasak, et al.; Biochem. 57, 5456 (2018)